Furosemide : List of nationally authorised medicinal products - PSUSA/00001491/202301

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic, Date of authorisation: 17/09/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Tuberculosis, Multidrug-Resistant, Date of authorisation: 31/07/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Lymphoma, Non-Hodgkin;Hodgkin Disease, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic;Psoriasis, Date of authorisation: 15/01/2015, Revision: 21, Status: Authorised

COVID-19 vaccines - Safety update: 14 July 2022

Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), Date of authorisation: 24/06/2022, Revision: 6, Status: Withdrawn

EU medicines agencies reflect on lessons learned from COVID-19